603O First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation

Robin Guo, Afshin Dowlati, Ibiayi Dagogo‐Jack, Julien Vibert, Alexander I. Spira, V. Moreno Garcia, Salman R. Punekar, E. Calvo, G.P. Sonpavde, Mark M. Awad, J.W. Riess, Teresa Cenarro Guerrero, Benjamin Herzberg, Antoîne Italiano, Aurélie Swalduz, Patricia LoRusso, E.F. Smit, E.B. Garon, William Novotny, Timothy A. Yap